Carta Revisado por pares

Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis

2024; American Medical Association; Linguagem: Inglês

10.1001/jama.2024.22730

ISSN

1538-3598

Autores

Krithika Loganath, Neil Craig, Russell J. Everett, Rong Bing, Vasiliki Tsampasian, Patrycja Mołek, Simona Botezatu, Saadia Aslam, Steff Lewis, Catriona Graham, Audrey White, Tom MacGillivray, Christopher Tuck, Phillip Rayson, Denise Cranley, S. Rodman Irvine, Ruth Armstrong, Lynsey Milne, Calvin Chin, Graham S. Hillis, Timothy Fairbairn, John P. Greenwood, Richard P. Steeds, Stephen J Leslie, Chim C. Lang, Chiara Bucciarelli‐Ducci, Nikhil Joshi, Vijay Kunadian, Vassilios S. Vassiliou, Jason Dungu, Sandeep S. Hothi, Nicholas A. Boon, Sanjay Prasad, Niall Keenan, Dana Dawson, Thomas A. Treibel, Manish Motwani, Christopher A. Miller, Nicholas L. Mills, Ronak Rajani, David P Ripley, Gerry P. McCann, Bernard Prendergast, Anvesha Singh, David E. Newby, Marc R. Dweck, Kush Patel, Mervyn Andiapen, Lucinda Wynne, Hunaid A. Vohra, Jodie Hussain, Kelly Patel, Stephen Dorman, Laura Gallego‐Yerga, Jonaifah Ramirez, Emily Redman, Sofia Matia, Madelaine Ocampo, Annaliza Sevilliano, Gracie Maloney, Amanda Solesbury, Steven Church, Lauren Kittridge, Jovita Rebong, Jacqueline Colnet, Johannes Pintacasi, James H. Morrissey, Anthony E. Tipping, Stephanie Hunt, Amy Raynsford, Daniel L. Cooke, Dan Sado, Jonathan Byrne, Abigail Knighton, Jonathan Breeze, Michail Sionas, J. Crawford Crowe, MAlvin Jose, Thabitha Charles, Anna Oommen, Victoria Clegg, April Edwards, Albert Trueman, Rajeev Padjama, Suzanne Higson, Martin Sherwood, Sarah Mackie, A. McNab, Preetha Mathew, Akhila Muthuswamy, Sujata Blane, Sheetal Crasta, Kathryn Walker, Anne Ankers, Philip McGrouther, Dean J. Miller, Denise O'Donell, Melanie Tolson, Anne Firor Scott, Fiona Hall, Gillian Donaldson, Su Ern Yeoh, Rachael Campbell, Debbie McDonald, Donna Patience, Natasha Corballise, Donna Moore, Mary Ilsley, Iain Matthews, Craig Runnett, Gemma McCafferty, Hayley McKie, Helen Campbell, Patrick A. Calvert, Kevin Bullock, Catherine Galloway, Tom Gilbert, L. David Hillis, Nicolas Nikolaidis, James Cotton, Giuseppe Ugo Rescigno, Elizabeth A. Radford, Jeetendra Thambyrajah, Neil Maredia, Ben A. Ward, Rachel Dale, Harish Sharma, Annette Nilsson, Helen Brotherton, Tabassuma Akramul, Kirk S. Hutton, Simon McDonald, Caroline Dykes, Vikki Timmins, Michael Bubb, K Isaacs, Alastair Mobley, Victoria Harries, Beverly MacLennan, Kashan Ali, Zaid Iskandar, Muhammad Asif Hussain, Marie Callaghan, Margaret Glenwright, Hilary Nailon, Frank Morrow, K. B. Orr, Caitlin Murray, A Geddes, Prudence Miyanza, Patricia Jeram, Danielle Deojee, Colin Berry, Anil Joseph, Robert Sykes, Ammani Brown, Kirsty Fallon, Shaela Doig, Laura Kelly, Tracey Hopkins, Laura Dymock, R. Woodward, Giles Roditi, Kate Smith‐Miles, Miroslawa Gorecka, Artemio Roxas, Petra Bijsterveld, Fiona Richards, R. Jude, Hannah Newman, Emma J. Grant, Kathryn Somers, Lynley Aldridge, Joanne Wormleighton, Jacob Mattakarottu Joseph, Xiaobei Zhao, Elaine F. Walker, Lillian Norris, Catherine L'Heureux, Robert Lee, Julia Boyd, Ronald Harkess, Helen Mossop, Nigel Masterton, Douglas W. Young,

Tópico(s)

Infective Endocarditis Diagnosis and Management

Resumo

Importance Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis. Objective To investigate whether early valve intervention reduced the incidence of all-cause death or unplanned aortic stenosis–related hospitalization in asymptomatic patients with severe aortic stenosis and myocardial fibrosis. Design, Setting, and Participants This prospective, randomized, open-label, masked end point trial was conducted between August 2017 and October 2022 at 24 cardiac centers across the UK and Australia. Asymptomatic patients with severe aortic stenosis and myocardial fibrosis were included. The final date of follow-up was July 26, 2024 Intervention Early valve intervention with transcatheter or surgical aortic valve replacement or guideline-directed conservative management. Main Outcomes and Measures The primary outcome was a composite of all-cause death or unplanned aortic stenosis–related hospitalization in a time-to-first-event intention-to-treat analysis. There were 9 secondary outcomes, including the components of the primary outcome and symptom status at 12 months. Results The trial enrolled 224 eligible patients (mean [SD] age, 73 [9] years; 63 women [28%]; mean [SD] aortic valve peak velocity of 4.3 [0.5] m/s) of the originally planned sample size of 356 patients. The primary end point occurred in 20 of 113 patients (18%) in the early intervention group and 25 of 111 patients (23%) in the guideline-directed conservative management group (hazard ratio, 0.79 [95% CI, 0.44-1.43]; P = .44; between-group difference, −4.82% [95% CI, −15.31% to 5.66%]). Of 9 prespecified secondary end points, 7 showed no significant difference. All-cause death occurred in 16 of 113 patients (14%) in the early intervention group and 14 of 111 (13%) in the guideline-directed group (hazard ratio, 1.22 [95% CI, 0.59-2.51]) and unplanned aortic stenosis hospitalization occurred in 7 of 113 patients (6%) and 19 of 111 patients (17%), respectively (hazard ratio, 0.37 [95% CI, 0.16-0.88]). Early intervention was associated with a lower 12-month rate of New York Heart Association class II-IV symptoms than guideline-directed conservative management (21 [19.7%] vs 39 [37.9%]; odds ratio, 0.37 [95% CI, 0.20-0.70]). Conclusions and Relevance In asymptomatic patients with severe aortic stenosis and myocardial fibrosis, early aortic valve intervention had no demonstrable effect on all-cause death or unplanned aortic stenosis–related hospitalization. The trial had a wide 95% CI around the primary end point, with further research needed to confirm these findings. Trial Registration ClinicalTrials.gov Identifier: NCT03094143

Referência(s)
Altmetric
PlumX